A simple method for assigning genomic grade to individual breast tumours
© Wennmalm and Bergh; licensee BioMed Central Ltd. 2011
Received: 25 February 2011
Accepted: 21 July 2011
Published: 21 July 2011
The prognostic value of grading in breast cancer can be increased with microarray technology, but proposed strategies are disadvantaged by the use of specific training data or parallel microscopic grading. Here, we investigate the performance of a method that uses no information outside the breast profile of interest.
In 251 profiled tumours we optimised a method that achieves grading by comparing rank means for genes predictive of high and low grade biology; a simpler method that allows for truly independent estimation of accuracy. Validation was carried out in 594 patients derived from several independent data sets. We found that accuracy was good: for low grade (G1) tumors 83- 94%, for high grade (G3) tumors 74- 100%. In keeping with aim of improved grading, two groups of intermediate grade (G2) cancers with significantly different outcome could be discriminated.
This validates the concept of microarray-based grading in breast cancer, and provides a more practical method to achieve it. A simple R script for grading is available in an additional file. Clinical implementation could achieve better estimation of recurrence risk for 40 to 50% of breast cancer patients.
KeywordsBreast Neoplasms Microarray Analysis Histology Prognosis Female
Decisions regarding medical treatment in early breast cancer are guided by disease stage, morphological characteristics (microscopic grading), and selected biological factors - notably expression of oestrogen and progesterone receptors and the HER2 oncogene . The prognostic and therapy-predictive accuracies of these factors are limited, resulting in over- and under-treatment of patients. A decade of experience from large scale gene expression studies have underscored the relevance of some factors, as well as indicated potential improvements. Retrospective data reveal a high degree of concordance between microarray-technology and established methods for determining oestrogen and progesterone receptor status [2–5], as well as expression of the HER2 oncogene . Concerning histopathological grading, two studies have indicated a potential for improvement. Here, the intermediate grade (G2) seems to lack a biological correlate. Both gene expression-wise and with regards to prognosis approximately two-thirds of G2-tumors are similar to the low grade group whereas about one third resemble the high grade group [7, 8], which means that 40-50% of breast cancer patients currently get an unnecessarily imprecise estimate of their risk of recurrence.
For research as well as clinical purposes, we have been interested to use proposed methods for microarray-based grading. The more extensively investigated method  - now commercially available through MapQuant Dx - involves calculation of a summary score from genes with increased expression in G1 and G3 cancers, respectively (weighted -1 and +1). To allow use across different microarray platforms, scores are transformed with scale and offset terms, calculated utilizing known microscopic grading in data to be classified, in a leave-one-out cross-validation. It is unclear if the leave-one-out approach adequately deals with the obvious risk of over-fitting, and the need for parallel microscopic grading is not appealing, rendering the method unpractical and insufficiently validated. The methods proposed by Ivshina et al  - prediction analysis of microarrays (PAM) and statistically weighted syndromes (SWS) - require training of the algorithm in the same original data for true reproduction, which is cumbersome and may deter potential users. Also, data to be classified may have to be normalized to training data to maintain accuracy. To validate and simplify the concept of microarray-based grading, we tested a method that only uses information contained in the single tumour profile of interest.
For Sotiriou's et. al.  set of 128 probe sets, the ranks (1 for a probe set with lowest expression in a given tumour profile, n for a gene with highest; n = number of probe sets on the microarray platform) were averaged for probe sets with increased expression in G3-tumors (n = 112), and those with increased expression in G1-tumors (n = 16), respectively. The higher average determines the genomic grade (we use Sotiriou's and co-workers term to distinguish from histopathological grade). Expression of grade-related genes is thus only related to other genes internal to the profile, resulting in a method that can classify individual profiles with no further information. Insensitivity to data set composition, no requirement for training data, and unbiased estimation of accuracy are key advantages. Sensitivity to differences in average expression between probes is a potential limitation.
Agreement in classification between microarray-based and microscopic grading in five published data sets
( N = 251)
( N = 147)
(N = 70)
(N = 82)
(N = 295)
Routine use of microarray or other RNA-profiling technology in early breast cancer is a likely future development, and projects to test this clinically are underway. Common to all these efforts is the aim to achieve improved prognostic and treatment predictive information. We take particular interest in microarray-based grading as it offers some key advantages over other proposed strategies (MammaPrint and Oncotype Dx etcetera): grade is well-known and interpretation in relation to clinical guidelines is straightforward. Change of practice - with the potential to spare patients from aggressive therapy - is likely to happen faster than with signatures introducing new taxonomies with unclear relationships to established prognostic and treatment predictive markers. Focusing on factors of known importance - like grade - also makes it possible to motivate microarray technology as an improvement in medical technology: similar or improved information (compared to that contributed by the pathology department) can be achieved at a competitive cost. Suggested methods to achieve this - in their current published form [7, 8] - are disadvantaged by methodological complexity and uncertain independent accuracy, which has motivated us to design a simpler data set-independent method and evaluate it in several tumour series. This can hopefully increase interest in the concept of microarray-based grading; an R script for the necessary calculations is available in an additional file (Additional file 2).
Availability and requirements
Acknowledgements and funding
We thank Dr Johanna Smeds and Anna-Lena Borg for valuable technical assistance. This work was supported by grants from the Swedish Cancer Society; the Stockholm Cancer Society; the King Gustav V jubilee fund; the ALF Foundation; the Linné Foundation; the Swedish Research Council; Manchester University; the BRECT consortium at Karolinska Institutet; and the Märit & Hans Rausing initiative against breast cancer.
- Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009, 20: 1319-1329. 10.1093/annonc/mdp322.View ArticlePubMedPubMed CentralGoogle Scholar
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.View ArticlePubMedGoogle Scholar
- Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS: Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 2001, 61: 5979-5984.PubMedGoogle Scholar
- van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530a.View ArticlePubMedGoogle Scholar
- Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, et al: Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008, 10: R65-10.1186/bcr2124.View ArticlePubMedPubMed CentralGoogle Scholar
- Bergqvist J, Ohd JF, Smeds J, Klaar S, Isola J, Nordgren H, Elmberger GP, Hellborg H, Bjohle J, Borg AL, et al: Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. Ann Oncol. 2007, 18: 845-850. 10.1093/annonc/mdm059.View ArticlePubMedGoogle Scholar
- Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, et al: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006, 66: 10292-10301. 10.1158/0008-5472.CAN-05-4414.View ArticlePubMedGoogle Scholar
- Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006, 98: 262-272. 10.1093/jnci/djj052.View ArticlePubMedGoogle Scholar
- Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA. 2005, 102: 13550-13555. 10.1073/pnas.0506230102.View ArticlePubMedPubMed CentralGoogle Scholar
- Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, et al: Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005, 7: R953-964. 10.1186/bcr1325.View ArticlePubMedPubMed CentralGoogle Scholar
- Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, et al: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007, 25: 1239-1246. 10.1200/JCO.2006.07.1522.View ArticlePubMedGoogle Scholar
- van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/306/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.